Ravi Sharma, MD
Interventional Cardiology · Louisville, KYNPI 1912211459
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 64.1% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2022 at $41,177 and has fallen 83.5% since, to $6,796 in 2025. Among interventional cardiology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 626 payments — averaging $138.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$55K
- Abbott$15K
- Edwards Lifesciences$4K
- Boston Scientific$3K
- AstraZeneca$991
- Terumo Medical Corporation$970
- plus $8K from 37 others
Across 3 payments — averaging $9156.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$23K
- Medtronic$5K
What the payments were for
- Consulting fees$7,0718%
- Speaking & faculty fees$40,47547%
- Travel & lodging$19,37422%
- Food & beverage$18,05021%
- Education$1,4992%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$36,128
- Diamondback Coronary$10,802
- CoreValve Evolut$7,443
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,116
- Resolute$1,362
- EKOSONIC$1,355
- TRICLIP$1,061
- METACROSS OTW$394
- DRAGONFLY OPSTAR$393
- AVVIGO Guidance System$266
- ANGIO-SEAL$264
- GLIDESHEATH SLENDER$255
- RESOLUTE ONYX$238
- FARXIGA$236
- Repatha$231
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$228
- Vascular Lithotripsy$172
- MANTA$155
- COROFLOW$154
- GlideWire$146
How this compares
$86,469 in reported general payments places this provider in the 90th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 164 | $152,572 |
| EliquisApixaban | 128 | $135,780 |
| JardianceEmpagliflozin | 111 | $113,407 |
| EntrestoSacubitril/Valsartan | 42 | $53,714 |
| XareltoRivaroxaban | 28 | $27,194 |
| BrilintaTicagrelor | 29 | $17,518 |
| Repatha SyringeEvolocumab | 16 | $9,923 |
| Repatha SureclickEvolocumab | 13 | $9,200 |
| Ranolazine ErRanolazine | 33 | $2,270 |
| Metoprolol Succinate | 217 | $2,162 |
| Atorvastatin Calcium | 244 | $1,657 |
| ClopidogrelClopidogrel Bisulfate | 171 | $1,316 |
| Ezetimibe | 36 | $1,166 |
| Pantoprazole Sodium | 44 | $749 |
| Rosuvastatin Calcium | 60 | $698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $991 | $170,089193 claims |
| PfizerEliquis | $676 | $135,780128 claims |
| Boehringer IngelheimJardiance | $199 | $113,407111 claims |
| NovartisEntresto | $946 | $53,71442 claims |
| Johnson & JohnsonXarelto | $548 | $27,19428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Louisville
- Daniel StewartLouisville$290K
- Daniel RothschildLouisville$154K
- Naresh SolankhiLouisville$132K
- Christopher SemderLouisville$50K
- Sadip PantLouisville$43K
- Michael FlahertyLouisville$42K
- Prafull RahejaLouisville$27K
- Faraaz RahmanLouisville$22K
- Hussayn AlrayesLouisville$21K
- Ivan PenaLouisville$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.